Compare SMWB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMWB | CTMX |
|---|---|---|
| Founded | 2007 | 2008 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 778.8M | 716.9M |
| IPO Year | 2021 | 2015 |
| Metric | SMWB | CTMX |
|---|---|---|
| Price | $9.00 | $2.53 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 8 |
| Target Price | $10.83 | ★ $12.25 |
| AVG Volume (30 Days) | 485.5K | ★ 4.0M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | ★ $76,201,000.00 |
| Revenue This Year | $11.98 | N/A |
| Revenue Next Year | $11.01 | $1.24 |
| P/E Ratio | ★ N/A | $22.58 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.22 | $2.43 |
| 52 Week High | $9.50 | $8.21 |
| Indicator | SMWB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 64.07 | 34.17 |
| Support Level | $7.83 | N/A |
| Resistance Level | $9.50 | $3.93 |
| Average True Range (ATR) | 0.42 | 0.14 |
| MACD | 0.11 | 0.00 |
| Stochastic Oscillator | 87.56 | 16.67 |
Similarweb Ltd provides digital data and analytics that power critical business decisions. The group recognizes revenue from subscriptions to the platform and other subscription products on a straight-line basis over the term of the contract subscription period beginning on the date access to the platform is granted, provided all other revenue recognition criteria have been met. It has geographic presence in Israel, the United States, the United Kingdom, Asia Pacific, Europe, and Other. The group generates the majority of its revenue from the United States.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.